On January 6, 2020 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") reported the status of acquisition of its own shares as stated below (Press release, Astellas, JAN 6, 2020, View Source [SID1234552693]). The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Particulars

1. Class of shares acquired: Common stock of the Company

2 Total number of shares acquired: 7,360,600 shares

3 Total amount of acquisition cost: 13,738,364,050 yen

4 Period of acquisition: From December 1, 2019 to December 23, 2019

5 Method of acquisition: Purchased on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on October 31, 2019)
-Class of shares to be acquired: Common stock of the Company

-Total number of shares to be acquired: Up to 32 million shares (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.70%)

-Total amount of acquisition cost: Up to 50 billion yen

-Period of acquisition: From November 1, 2019 to January 31, 2020

2. Accumulated Company’s own shares acquired through December 31, 2019, pursuant to the above board resolution

-Total number of shares acquired: 20,026,200 shares

-Total amount of acquisition cost: 36,866,306,500 yen